Vaxess Technologies

Vaxess Technologies is developing the MIMIX™ sustained release patch technology, the easiest and most effective way to administer vaccines and therapeutics. For vaccines, the controlled release simulates the pace of a natural infection, helping the body produce a slow, strong, and enduring ramp-up of immune response, ultimately boosting a vaccine’s effectiveness. Engineered for stability, Vaxess’s patch does not require refrigeration and can be shipped to and applied in low resource settings.

Vaxess Technologies headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical sector. The company focuses on Biotechnology and has secured $20.8B in funding across 240 round(s). With a team of 51-100 employees, Vaxess Technologies is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Vaxess Technologies, raised $3.8M. Discover more about their projects, partnerships, and impact on our platform.